section name header

Indications ⬇

IM: IM:

REMS


Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: facial flushing, rash

EENT: nasal onlyrhinitis, epistaxis, nasal irritation

GI: IM, SUBQnausea, vomiting

GU: IM, SUBQurinary frequency

Local: injection site reactions

MS: nasalarthralgia, back pain

Neuro: nasal onlyheadaches

Misc: MALIGNANCY, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Postmenopausal osteoporosis

Paget’s disease

Hypercalcemia

US Brand Names ⬆ ⬇

Miacalcin

Action ⬆ ⬇

  • Inhibits osteoclastic bone resorption and promotes renal excretion of calcium.
Therapeutic effects:
  • Decreased rate of bone turnover.
  • Lowering of serum calcium.

Classifications ⬆ ⬇

Therapeutic Classification: hypocalcemics

Pharmacologic Classification: hormones

Pharmacokinetics ⬆ ⬇

Absorption: Completely absorbed from IM and SUBQ sites. Rapidly absorbed from nasal mucosa; absorption is 3% compared with parenteral administration.

Distribution: Unknown.

Metabolism/Excretion: Rapidly metabolized in kidneys, blood, and tissues.

Half-Life: 40–90 min.

Canadian Brand Names ⬆ ⬇

Calcimar

Time/Action Profile ⬆ ⬇

ROUTEONSETPEAKDURATION
IM, SUBQ‡unknown2 hr6–8 hr
Intranasal‡rapid31–39 minunknown

‡Effects on serum calcium; effects on serum alkaline phosphates and urinary hydroxyproline in Paget's disease may require 6–24 mo of continuous treatment.

‡Serum levels of administered calcitonin.

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆

kal-si-TOE-nin